Clearmind Medicine Inc. (NASDAQ:CMND – Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 88,087 shares, a decrease of 56.7% from the June 30th total of 203,361 shares. Approximately 8.6% of the company’s shares are sold short. Based on an average daily volume of 1,322,969 shares, the short-interest ratio is currently 0.1 days.
Insider Buying and Selling
In other news, major shareholder Financial Lp Hrt bought 2,159,052 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was acquired at an average price of $0.15 per share, with a total value of $323,857.80. Following the transaction, the insider owned 2,063,266 shares of the company’s stock, valued at $309,489.90. This trade represents a -2,254.04% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 252,615 shares of company stock worth $117,933.
Clearmind Medicine Stock Down 0.3%
CMND traded down $0.01 during trading on Wednesday, hitting $1.46. 32,266 shares of the company’s stock were exchanged, compared to its average volume of 1,082,633. Clearmind Medicine has a fifty-two week low of $1.43 and a fifty-two week high of $524.00. The stock has a market cap of $1.48 million, a P/E ratio of -0.01 and a beta of 0.74. The business’s 50 day moving average is $2.53 and its two-hundred day moving average is $9.00.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 20th.
Get Our Latest Stock Report on Clearmind Medicine
About Clearmind Medicine
Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.
Clearmind’s pipeline includes multiple preclinical and early clinical candidates.
Read More
- Five stocks we like better than Clearmind Medicine
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
- Meta’s AI Spending Problem Just Found a BlackRock Solution
Receive News & Ratings for Clearmind Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearmind Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
